We're buying more of this life sciences stock after an earnings-driven decline

  • 📰 CNBC
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 72%

Nigeria News News

Nigeria Nigeria Latest News,Nigeria Nigeria Headlines

The stock is under pressure in early trading due to uncertainty around the recovery in a key business.

We're buying 30 shares of Danaher at roughly $199 each. Following Tuesday's trade, Jim Cramer's Charitable Trust will own 550 shares of DHR, increasing its weighting in the portfolio to 4.08% from 3.87%. Danaher reported a better-than-expected third-quarter Tuesday morning, but the stock is under pressure in early trading due to uncertainty around the recovery in its bioprocessing business. For the quarter, Danaher revenues fell 10.5% to $6.87 billion, beating estimates of $6.

Danaher pointed out that its bioprocessing orders were down in the third quarter versus the second quarter and were expected to decline again in the fourth. We pay close attention to orders because they precede sales. Danaher's view that orders will decline over the next two quarters contrasts the upbeat data point its bioprocessing peer Sartorious said last week.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in NG

Nigeria Nigeria Latest News, Nigeria Nigeria Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

US Stock Market's Stellar 2023 Run Under Threat as Bond Vigilantes Make a ComebackStocks Analysis by James Picerno covering: Vanguard Total Stock Market Index Fund ETF Shares, LPL Financial Holdings Inc, United States 10-Year, SPDR® Bloomberg High Yield Bond ETF. Read James Picerno's latest article on Investing.com
Source: Investingcom - 🏆 450. / 53 Read more »

The stock market may be ignoring this 'bad news' as earnings get under way‘Stealth stagnation’ has gone under the radar, says BlackRock team
Source: MarketWatch - 🏆 3. / 97 Read more »